ライフサイエンスコーパス: radionuclide

1 hly suitable carriers of therapeutic (188)Re radionuclide.

2 herapeutic and the physical half-life of the radionuclide.

3 it as a substitute for a generic therapeutic radionuclide.

4 ith an internally incorporated beta-emitting radionuclide.

5 may be a new production path for this useful radionuclide.

6 ere length among tissues in voles exposed to radionuclides.

7 e opportunities to improve patient care with radionuclides.

8 e detection of miniscule quantities of these radionuclides.

9 1 h, corresponding to ~99% removal of trace radionuclides.

10 ould aid interventional procedures involving radionuclides.

11 specific molecules bearing positron-emitting radionuclides.

12 itative toxicity assessment of environmental radionuclides.

13 species with positron- or gamma-ray-emitting radionuclides.

14 ted for image-guided delivery of therapeutic radionuclides.

15 or the speciation-sensitive ecotoxicology of radionuclides.

16 the half-lives of (211)At and shorter-lived radionuclides.

17 s from delivery of diagnostic or therapeutic radionuclides.

18 therapy, brachytherapy, and various injected radionuclides.

19 ence of naturally occurring or anthropogenic radionuclides.

20 AFs and the corresponding S values for 1,252 radionuclides.

21 e applicable to other accidental releases of radionuclides.

22 er studies involving bioremediation of these radionuclides.

23 production rate variations of the cosmogenic radionuclide (10)Be in different archives provides a too

24 , the short half-lives of the currently used radionuclides (11)C (20.4 min) and (18)F (109.8 min) may

25 They were labelled with the radionuclide (131) I (beta(-) /gamma emitter, t1/2 8.02

26 iation dosimetry were compared for different radionuclides ((131)I, (134,137)Cs, (90)Sr-(90)Y, (103)R

27 nd (232)Th and their progeny) and artificial radionuclides ((137)Cs) in various honey samples, as wel

28 Fallout radionuclides ((137)Cs, (239)Pu, (240)Pu) were measured

29 oimmunotherapy (PRIT) with the beta-emitting radionuclide (177)Lu is an attractive approach to treat

30 iO(2) nanoparticles, and the activity of the radionuclide (18)F-FDG-on the number of photons and ROS

31 and radiolabeled with the positron-emitting radionuclide (64)Cu (half-life, 12.7 h).

32 Herein, a radionuclide-(64) Cu-labeled doxorubicin-loaded polydopa

33 des a diagnostic partner for the therapeutic radionuclide (67)Cu.

34 The short-lived PET radionuclide (68)Ga, available on a regular basis from a

35 was radiolabeled with the positron-emitting radionuclide (89)Zr.

36 had been printed, SPECT/CT acquisitions of 3 radionuclides ((99m)Tc, (177)Lu, and (131)I) were obtain

37 ion and size of TiO(2) nanoparticles and the radionuclide activity needed for efficient cancer therap

38 per cell increased over the first 3 h after radionuclide administration and decreased thereafter.

39 The migration of each of these radionuclide analogs (RAs) was shown to be dependent upo

40 Natural radionuclides and (137)Cs in twenty seven honeys produce

41 d or optimized approaches for novel emerging radionuclides and carriers in development.

42 diagnostic and therapeutic payloads such as radionuclides and drugs into neoplastic masses.

43 e model described here can be used for other radionuclides and nanoparticles and can provide guidance

44 n contrast to conventional RID/RIT where the radionuclides and oncotropic vector molecules are delive

45 y low tumor-targeting efficiency of existing radionuclides and radionuclide-based nanomedicines limit

46 global environment, including technofossils, radionuclides and the exponential increases of methane a

47 Finally, alternative theranostic radionuclides and treatment strategies are discussed.

48 on of metallo-compound radiosensitizers with radionuclides and within drug delivery approaches.

49 media, high radiopurity (lack of concomitant radionuclides), and volatility between 700 and 1,000 deg

50 nvironment heterogeneously contaminated with radionuclides, and from uncontaminated control sites els

51 We performed equilibrium radionuclide angiography (ERNA) before and 6 mo after CR

52 evolution and development of the theranostic radionuclide approach to the management of neuroendocrin

53 We find that radionuclides are absent from all Majuro soil samples, a

54 Radionuclides are present in groundwater at contaminated

55 Uranium and other radionuclides are prominent in many unconventional oil/g

56 illing moieties, including toxins, drugs, or radionuclides, are chemically or genetically linked to m

57 tion and the gamma and beta scintillation of radionuclides, as well as on their biological applicatio

58 re, FAP is considered a promising target for radionuclide-based approaches for diagnosis and treatmen

59 ranostic agents, which enables precision and radionuclide-based combination tumor therapy.

60 ing efficiency of existing radionuclides and radionuclide-based nanomedicines limits the efficacy of

61 The development and application of radionuclide-based reporter systems is the focus of this

62 What is required for moving forward with radionuclide-based reporter systems, and what is require

63 scent and bioluminescent proteins as well as radionuclide-based reporter systems.

64 ovide new information about dynamic iron and radionuclide biogeochemistry throughout realistic sedime

65 ion-theoretic model selection suggested that radionuclide biokinetics, e.g. for plutonium in humans,

66 As the dominant radionuclide by mass in many radioactive wastes, the con

67 environmental transport and uptake of heavy radionuclides by marine species.

68 energy photon emissions from the therapeutic radionuclide can be highly attenuated, still allowing su

69 Cerenkov radiation (CR) from radionuclides can act as a built-in light source for can

70 of PSMA radiolabeled with positron-emitting radionuclides can be used for diagnostic imaging with po

71 The positron-emitting radionuclide carbon-11 ((11)C, t1/2 = 20.3 min) possesse

72 with the positron emission tomography (PET) radionuclide carbon-11 ([(11)C]biotin) to enable the qua

73 However, increased radionuclide concentration alters its speciation, render

74 u-lilotomab satetraxetan is a novel antibody-radionuclide conjugate currently in a phase 1/2a first-i

75 b satetraxetan is a novel anti-CD37 antibody-radionuclide conjugate currently in phase 1/2a.

76 u-lilotomab satetraxetan is a novel antibody radionuclide conjugate currently tested in a phase 1/2a

77 vestigated as a model system for engineering radionuclide containing materials through utilization of

78 lareolus in areas that contrast in levels of radionuclide contamination (Chernobyl, Ukraine).

79 cations for the interpretation of cosmogenic radionuclide data and resulting total solar irradiance e

80 trontium-90 ((90)Sr) is the major long-lived radionuclide derived from the Chernobyl accident, and is

81 However, most radionuclide detection methods have spatial resolution i

82 Current research on radionuclide disposal is mostly conducted in granite, cl

83 pare agents labeled with a positron-emitting radionuclide (e.g., (18)F).

84 s with technetium-99, one of the most mobile radionuclides encountered.

85 tons produced when the positron emitted by a radionuclide encounters an electron and is annihilated.

86 Finally, the article examines whether radionuclide examinations might be able to play an expan

87 romising strategy to enhance the analysis of radionuclide excretion and retention kinetics.

88 Modelling the biokinetics of radionuclide excretion or retention is important in nucl

89 Dual radionuclide experiments in which a single administratio

90 ly to establish a baseline in case of future radionuclide fallout but also to define a baseline for g

91 Fluorine-18 (t(1/2) = 109.8 min) is a major radionuclide for labeling such radiotracers but is only

92 (15)O (half-life, 122 s) is a useful radionuclide for PET applications.

93 Selecting a radionuclide for theranostic purposes generally starts b

94 Astatine-211 is an attractive radionuclide for use in targeted alpha therapy of blood-

95 capacity, which can not only chelate (64) Cu radionuclides for positron emission tomography (PET) ima

96 for imaging and with beta- and alpha-emitter radionuclides for radioimmunotherapy.

97 210)Po and (90)Sr, two of the most important radionuclides for radiological dose from the ingestion p

98 ess in the clinic with several beta-emitting radionuclides for the treatment of ovarian cancer.

99 tibody-related therapeutics labeled with PET radionuclides for theranostic purposes in patients.

100 agnitude of the transfer to milk of elements/radionuclides for which no relevant data have yet been i

101 tudies have found elevated levels of fallout radionuclides (FRNs) and other contaminants in glacial s

102 eiving a considerable input of anthropogenic radionuclides from nuclear reprocessing facilities locat

103 Stable-element proxies show that radionuclides from the Trinity device were chemically, b

104 mplexes with either of the positron-emitting radionuclides gallium-68 (t(1/2) = 68 min) or zirconium-

105 , Trinity, are reliable chemical proxies for radionuclides generated during the explosion.

106 scales by coupling high-precision cosmogenic radionuclide geochronology and rigorous numerical modeli

107 so offer a wide range of options in terms of radionuclide half-lives and emission properties, providi

108 the AKP, bank voles that are not exposed to radionuclides harbour variable (increased inter-individu

109 rapy of solid tumors using antibody-targeted radionuclides has been limited by low therapeutic indice

110 abeling of somatostatin analogs with various radionuclides has led to a revolution in patient managem

111 Molecularly targeted radionuclides have great potential for cancer therapy bu

112 Targeted alpha-particle-emitting radionuclides have great potential for the treatment of

113 Conversely, bank voles exposed to radionuclides host more similar gut microbiota communiti

114 feasibility of using anti-PD-L1 antibody for radionuclide imaging and radioimmunotherapy and highligh

115 ted alterations of molecular phenotype using radionuclide imaging is a noninvasive approach to strati

116 Radionuclide imaging of myocardial perfusion, function,

117 e resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainst

118 Radionuclide imaging with [(18)F]BF4(-) (PET/CT) was com

119 This is a unique selling point of radionuclide imaging, which has been underrecognized in

120 ow that both fallout sources left a specific radionuclide imprint in European soils.

121 Uranium is a risk-driving radionuclide in both radioactive waste disposal and cont

122 the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitat

123 n, resulting in a certain percentage of free radionuclide in the body.

124 portant medium of transport for the released radionuclides in a respirable form.

125 cokinetics to efficiently deliver and retain radionuclides in a tumor.

126 tive aerosols, including the transmission of radionuclides in different chemical matrices throughout

127 6/52/Euratom updates the emergency limits on radionuclides in foods including (210)Po and (90)Sr, two

128 argoes, such as ceramics and fertilizers, or radionuclides in recently treated nuclear medicine patie

129 the activity-level of natural and artificial radionuclides in some baby foods commercialized in Italy

130 considered in the migration model of Cs and radionuclides in the current environment surrounding the

131 s, (134)Cs, (131)I, and other gamma-emitting radionuclides in the ocean, but minor work was done rega

132 human and animal data sets involving various radionuclides (including plutonium, strontium, caesium)

133 uld be effective in capturing these volatile radionuclides, including (85)Kr.

134 and animals, while permitting facile (18) F radionuclide incorporation required for PET imaging.

135 diolabeling with the Auger electron-emitting radionuclide indium-111 ((111)In).

136 obyl accident have released large amounts of radionuclides into the environment.

137 uch attention but the chemistry by which the radionuclide is conjugated to the protein scaffold is of

138 o managing this highly mobile and long-lived radionuclide is immobilization into micro- and meso-poro

139 radioactive), selective accumulation of the radionuclides is desirable to minimize the volume of nuc

140 , diagnostic accuracy with positron-emitting radionuclides is greater than 90%.

141 accelerators, nuclear reactors and clinical radionuclides, it has been used in applications such as

142 cept involves the use of very low doses of a radionuclide-labeled compound for imaging studies or for

143 , as well as the pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ.

144 d the first-in-human treatment with an alpha-radionuclide-labeled PSMA ligand.

145 Emission of radiation from the RPT radionuclide may disturb coincidence detection and impai

146 )Po in autopsy tissues suggest that airborne radionuclides may contribute to the development of chron

147 Molecular radiotherapy with tumor-targeted radionuclides may overcome some of these challenges, but

148 A cosmogenic radionuclide measured at ground-level, beryllium-7, is u

149 ty fracture networks that may result in high radionuclide mobility.

150 ty protein (ADAPT) is a promising tracer for radionuclide molecular imaging because of its small size

151 Radionuclide molecular imaging of human epidermal growth

152 ogies are linked by the requirement that the radionuclide must be attached to a suitable vector that

153 Heretofore, radionuclide myocardial perfusion imaging has been prima

154 Here, we show that a dual radionuclide-near-infrared probe allows for quantitative

155 In contrast, (90)Sr is a radionuclide of sole anthropogenic origin, produced by n

156 However, when using radionuclides of 2 different elements, differences in th

157 tic agents that incorporate the matched-pair radionuclides of scandium-(43)Sc/(47)Sc or (44)Sc/(47)Sc

158 The choice of radionuclide or chelate, and its impact on the thermodyn

159 ue physicochemical properties, allows vector-radionuclide pairings to be matched to the molecular, pa

160 Innovative SPECT radionuclide pairs have now become available for radiola

161 cal analyses were performed on the following radionuclides: plutonium-(239,240), plutonium-238, ameri

162 agents, but the rapid physical decay of the radionuclide poses logistic and regulatory challenges.

163 d has a half-life of 29 years; each of these radionuclides poses potential threats to human and ecosy

164 eement with the abundance of (53)Mn, another radionuclide present in the early solar system and produ

165 Beryllium-7 has two advantages: First, this radionuclide, primarily created in the lower stratospher

166 The subsequent radionuclide production, experimental setup, (18)F label

167 that new technologies, primarily related to radionuclide production, have provided solutions to thes

168 ne regarding the monitoring of less volatile radionuclides, pure beta-ray emitters or simply radionuc

169 l plaques/carotid arteries by an experienced radionuclide radiologist and radiographer.

170 It is imperative that the radionuclide remain attached to the vector before it is

171 -site or atmospheric signatures of noble gas radionuclides resulting from the event.

172 teractions between natural and anthropogenic radionuclides, seawater, and diverse marine biota provid

173 Radionuclide signals from underground nuclear explosions

174 ng Bayesian algorithm capable of identifying radionuclide signatures from weak sources in the presenc

175 impurities which have been shown to enhance radionuclide sorption via titanium's influence on the Fe

176 ide suitable conditions for certain types of radionuclide storage (in particular, brackish, high-poro

177 ss of metal removal, regardless of the model radionuclide studied.

178 The limitations of clinical and radionuclide studies are then reviewed.

179 follow-up and was further characterized with radionuclide studies consisting of PET-CT and MIBG scint

180 ast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/CT (C) RSNA, 2020.

181 PRIT might be improved using alpha-emitting radionuclides such as (213)Bi.

182 aste can influence the migration behavior of radionuclides such as curium (Cm(III)).

183 chanism by which volatile and low-volatility radionuclides such as U can reach the environment and sh

184 used nuclear fuel is the release of volatile radionuclides such as xenon and krypton that evolve into

185 ong-lived positron emission tomography (PET) radionuclides, such as manganese-52 ((52)Mn, T(1/2)=5.6d

186 gh in vitro labeled leukocyte imaging is the radionuclide test of choice for complicating osteomyelit

187 (161)Tb is a medium-energy beta(-) radionuclide that is similar to (177)Lu but emits a high

188 Theranostic strategies involve select radionuclides that allow diagnostic imaging and tailored

189 hod for the cyclotron production of scandium radionuclides that could be used with natural or enriche

190 Capture and storage of volatile radionuclides that result from processing of used nuclea

191 ssues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with

192 The nature of interaction between radionuclides, the marine environment, and marine specie

193 or receptor type 2 (HER2)-VHH1 is a targeted radionuclide theranostic agent directed at HER2-expressi

194 titative SPECT/CT, voxel-based dosimetry for radionuclide therapies has aroused growing interest as i

195 Of all participating centers, 81% performed radionuclide therapies, and they reported a reduction of

196 diation sensitizers, chemotherapy, and other radionuclide therapies, are being evaluated.

197 rowing interest in voxel-based dosimetry for radionuclide therapies, because it promises visualizatio

198 -DOTATATE was initiation of peptide receptor radionuclide therapy (14 patients, 27.4%).

199 Peptide receptor radionuclide therapy (PRRT) has become a well-accepted t

200 Peptide receptor radionuclide therapy (PRRT) has been used for more than

201 tion-based index (IBI), for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET

202 tion-based index (IBI), for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumor (NET

203 Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy th

204 Peptide receptor radionuclide therapy (PRRT) is an effective treatment fo

205 -Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide therapy (PRRT) is an effective treatment fo

206 Peptide receptor radionuclide therapy (PRRT) is an important treatment op

207 Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicit

208 ta are available concerning peptide receptor radionuclide therapy (PRRT) of grade 3 (G3) neuroendocri

209 in receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising appro

210 Peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotat

211 Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatosta

212 addition, OS in relation to peptide receptor radionuclide therapy (PRRT) was analyzed as an explorato

213 Peptide receptor radionuclide therapy (PRRT) with (177)Lu-labeled somatos

214 nistration of (90)Y-DOTATOC peptide receptor radionuclide therapy (PRRT) would increase treatment eff

215 Peptide receptor radionuclide therapy (PRRT), such as (177)Lu-PSMA-617, i

216 e for the administration of peptide receptor radionuclide therapy (PRRT).

217 ocrine tumor, responding to peptide receptor radionuclide therapy (PRRT).

218 receptors qualifies it for peptide receptor radionuclide therapy (PRRT).

219 te-specific membrane antigen (PSMA)-targeted radionuclide therapy (RNT) may increase tumor immunogeni

220 rm of external beam radiotherapy or targeted radionuclide therapy (TRT) alongside radiosensitizing sm

221 In recent years, targeted radionuclide therapy (TRT) has emerged as a promising st

222 Targeted radionuclide therapy (TRT) is a branch of cancer medicin

223 M600) radiolabeled with (177)Lu for targeted radionuclide therapy (TRT) of TNBC.

224 ses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer.

225 ue opportunity for PET image-guided targeted radionuclide therapy and combination with immunotherapie

226 mprove the safety window of peptide receptor radionuclide therapy by reducing the liver and bone marr

227 Performing PET imaging during ongoing radionuclide therapy can be a promising method to follow

228 Conclusion: Peptide receptor radionuclide therapy can lead to bowel obstruction in pa

229 sh the potential for antibody-targeted alpha-radionuclide therapy for ovarian cancer, which may be ge

230 ul development and increased use of targeted radionuclide therapy for treating cancer comes the incre

231 results suggest that (177)Lu-NM600 targeted radionuclide therapy has potential for TNBC and merits f

232 ur experience with (177)Lu-PSMA-617-targeted radionuclide therapy in a case series of mCRPC patients

233 Peptide receptor radionuclide therapy in advanced neuroendocrine tumors (

234 Further study of peptide receptor radionuclide therapy in patients with small lesions nega

235 into receptor-targeting melanoma imaging and radionuclide therapy in the future.

236 s that allow diagnostic imaging and tailored radionuclide therapy in the same patient.

237 Peptide receptor radionuclide therapy is a new frontier in personalised m

238 endocrine tumors, access to peptide receptor radionuclide therapy is increasing.

239 ositive recommendations for peptide-receptor radionuclide therapy occurred in observers with low expe

240 1)At, is remarkably well suited for targeted radionuclide therapy of cancer.

241 ne antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistan

242 e receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors.

243 ing alkylphosphocholine (NM600) for targeted radionuclide therapy of TNBC.

244 ommendations for or against peptide-receptor radionuclide therapy require experience and training.

245 Radionuclide therapy targeting prostate-specific membran

246 Eligibility for somatostatin receptor (SSTR) radionuclide therapy uses the qualitative Krenning score

247 radioiodine label creates a precondition for radionuclide therapy using (131)I-labeled HPEM-Cys(59)-A

248 rs (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin ana

249 ions of appropriateness for peptide-receptor radionuclide therapy varied more significantly among obs

250 the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be more effective

251 ars was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, su

252 successfully used for clinical PET imaging, radionuclide therapy, and radioguided surgery of metasta

253 ever, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising

254 osimetry for (67)Cu-SARTATE peptide receptor radionuclide therapy, and the half-life of (64)Cu would

255 nt of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and mole

256 rapeutic index achieved with modern targeted radionuclide therapy, combined with quantitative PET and

257 prostate-specific membrane antigen-directed radionuclide therapy.

258 discovery, clinical diagnosis, and targeted radionuclide therapy.

259 suitability of patients for peptide receptor radionuclide therapy.

260 sted as a radioprotector in peptide receptor radionuclide therapy.

261 alive more than 12 y after the beginning of radionuclide therapy.

262 exendin were to be used for peptide receptor radionuclide therapy.

263 established target for molecular imaging and radionuclide therapy.

264 ualify for and benefit from peptide receptor radionuclide therapy.

265 entiated thyroid cancer and peptide receptor radionuclide therapy.

266 ing low-energy beta- and alpha-emitters, for radionuclide therapy.

267 (213)Bi (half-life, 46 min) is promising for radionuclide therapy.

268 dneys, creating preconditions for palliative radionuclide therapy.

269 6)Y for PET imaging and (177)Lu for targeted radionuclide therapy.

270 inal obstruction related to peptide receptor radionuclide therapy.

271 bone marrow radiation damage during targeted radionuclide therapy.

272 ctice of NM, clinical molecular imaging, and radionuclide therapy; and suggest a path forward for an

273 s barely shortened, enabling the transfer of radionuclides through an almost-intact food chain.

274 labeled probes have been dual-labeled with a radionuclide to enable cross-validation with nuclear ima

275 es to target both diagnostic and therapeutic radionuclides to melanoma cells for imaging and therapy.

276 In this in situ radionuclide tracer test, the environmental behavior of

277 Furthermore, models of radionuclide transport from disposal boreholes must take

278 DNA double-strand breaks in cells of radionuclide-treated patients are quantifiable by immuno

279 edicine and the associated need for accurate radionuclide treatment dosimetry will likely drive the u

280 ate-specific membrane antigen ((177)Lu-PSMA) radionuclide treatment in metastatic castration-resistan

281 n the preclinical guidance and prediction of radionuclide tumor sensitivity by identifying intrinsic

282 lecules constitute a new class of probes for radionuclide tumor targeting.

283 on with (177)Lu as one of the most important radionuclides used in molecular radiotherapies and to co

284 Almost all radionuclides used in RPT emit photons that can be image

285 valuation of Survival Trial measured LVEF by radionuclide ventriculography at baseline and at 3 and 1

286 nd calibration constants determined for each radionuclide-volume combination.

287 The anatomical distribution of the radionuclide was visualized using autoradiography at pre

288 resolution when both a PET and a therapeutic radionuclide were in the PET system.

289 eless, tumor-to-tissue uptake ratios of both radionuclides were comparable, indicating that drug-labe

290 Scandium radionuclides were purified via ion-exchange chromatogra

291 atin receptor antagonists and alpha-emitting radionuclides, which may further enhance treatment outco

292 lso produce telltale patterns of short-lived radionuclides, which would be preserved today as isotopi

293 ents that can be radiolabeled with (64)Cu, a radionuclide with a half-life of 12.7 h, ideal for PET i

294 (226)Ra is a naturally occurring radionuclide with a half-life of 1600 years.

295 One such product is (60)Fe, a radionuclide with a half-life of 2.6 My that is predomin

296 Gallium-68 ((68)Ga) is a generator-produced radionuclide with a short half-life (t(1/2) = 68 min) th

297 increased interest in theranostics using PET radionuclides with a relatively long physical half-life,

298 foils and pressed TiO(2) to produce scandium radionuclides with proton energies of up to 24 MeV.

299 ionuclides, pure beta-ray emitters or simply radionuclides with very long half-lives.

300 ratumumab labeled with the positron-emitting radionuclide zirconium 89 ((89)Zr) through the chelator